Clostridioides difficile is an anaerobic spore-forming Gram-positive bacterium. C. difficile carriage and 16S rDNA profiling were studied in three clinical groups at three different sampling times: inflammatory bowel disease (IBD) patients, C. difficile infection (CDI) patients …

Clostridioides difficile infection (CDI) may recur in approximately 10-30% of patients, and the risk of recurrence increases with each successive recurrence, reaching up to 65%. C. difficile can form biofilm with approximately 20% of the bacterial genome expressed differently between b …

Clostridioides difficile is the most important pathogen causing antimicrobial-associated diarrhea and has recently been recognized as a cause of community-associated C. difficile infection (CA-CDI). This study aimed to characterize virulence factors, antimicrobial resistance (AMR), rib …

Clostridioides difficile infection is expected to become the most common healthcare-associated infection worldwide. C. difficile-induced pathogenicity is significantly attributed to its enterotoxin, TcdA, which primarily targets Rho-GTPases involved in regulating cytoskeletal and tight …

Clostridioides difficile is a predominant nosocomial pathogen within the healthcare setting able to produce biofilms. Sub-minimum inhibitory concentrations (sub-MICs) of antibiotics trigger mechanisms affecting bacterial virulence, including increased adhesion and biofilm formation. The aim o …

Though antibiotics are the mainstay treatment for Clostridioides difficile, a large population of individuals infected will experience recurrence. In turn, fecal microbiota transplantation (FMT) has emerged as a promising treatment for recurrent C. difficile infection (rCDI). Mechanist …

Clostridioides difficile infection (CDI) has been increasingly observed in children, but there is a lack of epidemiological and molecular data on CDI in Latin America. This prospective cohort study aimed to investigate the role of CDI in children with diarrhea. It included 105 children with antimicr …

BACKGROUND Clostridioides difficile (C. difficile) is a bacterium that is well known for causing serious diarrheal infections and can even lead to colon cancer if left untreated. Disruption of the normal healthy bacteria in the colon can lead to development of C. difficile colitis. Risk factors for …

Health care facility floors and sink drains and other wastewater drainage sites are universally contaminated with potential pathogens and there are plausible mechanisms by which organisms can be disseminated from these sites. However, floors and sink drains are not addressed as potential sources of …

Clostridioides difficile (C. diff.) infection (CDI) is a leading cause of hospital acquired diarrhea in North America and Europe and a major cause of morbidity and mortality. Known risk factors do not fully explain CDI susceptibility, and genetic susceptibility is suggested by the fact that some pat …

The 31-year-old, from Houston, was diagnosed with C. diff, a highly contagious infection that throws the digestive system off balance and leads to painful inflammation in the colon.

Lab experiments support treating inflammation rather than bacteria

A chemical engineer at the University of Alberta has developed a disinfectant that is more effective than purely alcohol-based products, just by adding salt.

If you have UC, you’re more susceptible to this serious infection. Here’s what you need to know to protect yourself.

While inflammation is involved in both of these conditions, they have some important distinctions.

Clostridioides difficile (C. diff) intestinal infections can cause severe, debilitating diarrhea in patients who are hospitalized or on immunosuppressive therapies. The infections can be very hard to ...

New phase 1B data support further investigation into Adiso Therapeutic's prospective treatment.

The following is a summary of “Does clinician-initiated Clostridioides difficile testing improve outcomes of patients with Clostridioides Difficile infection?” published in the October 2023 issue of Infectious Control by Bartlett, et al. Clostridioides difficile (C. difficile) is a common illness that people get in hospitals. It can have serious effects on patients and our healthcare

LITTLE RIVER, SC, Oct. 30, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - PCT LTD (“PCTL” OTC Pink): Paradigm Convergence Technologies Corp (a Subsidiary of PCTL) manufactures, sells and leases equipment which produce a variety of EPA approved, eco-friendly disinfectant and degreaser fluids, is proud to announce its partnership with HypoClean, LLC a Colorado corporation specializing in hypochlorous acid (HOCl) technology and Veteran Commercial Cleaning, LCC, a global professional, commercial cleani

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.

The effectiveness of fecal microbiota transplantation (FMT) in ulcerative colitis (UC) remains unclear. This study aimed to investigate the feasibility and effectiveness of serial fecal infusions via colonoscopy in patients with active UC. Subjects with mild-to-moderate UC received three consecutive …

These data suggest that IBD patients, potentially due to underlying intestinal dysbiosis, experience undiagnosed C. difficile infections that result in impaired toxin-specific immunity. This may contribute to the development of inflammatory T cell responses toward commensal bacteria and provide a ra …

Findings from this study demonstrate the importance of underlying chronic conditions in the development of recurrent C. difficile disease and the shortcomings of current treatment options for recurrent cases. Additionally, our findings indicate that initial treatment selection may impact the likelih …

VANCOUVER, British Columbia — In this Healio video exclusive, Paul Feuerstadt, MD, FACG, AGAF, discusses the evolution of treatment for Clostridioides difficile infection, from antimicrobials to recently FDA-approved live biotherapeutics. “It’s so important for us to understand that C. diff has a major impact on our society,” Feuerstadt, assistant clinical professor of

The results obtained from the present basic experiments could suggest that teicoplanin is a potential antibiotic for the treatment of severe CDI with recurrence-prevention activity.

C. diff infection can cause severe intestinal inflammation. A new approach blocks the inflammation triggered by C. diff’s toxin.

Feuerstadt reviews ACG 2023 data showing live microbiota therapy provides consistent protection against rCDI in one of the most vulnerable patient populations.

Discover how live bacterial therapeutics can be used to treat diseases, and what the future of microbiome-based treatments looks like.

These data suggest that IBD patients, potentially due to underlying intestinal dysbiosis, experience undiagnosed C. difficile infections that result in impaired toxin-specific immunity. This may contribute to the development of inflammatory T cell responses toward commensal bacteria and provide a ra …

Findings from this study demonstrate the importance of underlying chronic conditions in the development of recurrent C. difficile disease and the shortcomings of current treatment options for recurrent cases. Additionally, our findings indicate that initial treatment selection may impact the likelih …